Xenova TransMID Enters Phase III For Brain Cancer Under Revised Special Protocol Assessment
This article was originally published in The Pink Sheet Daily
Executive Summary
Company believes replacing the single large Phase III trial originally proposed by TransMID innovator KS Biomedix with two smaller sequential trials will reduce the level of risk for the transferrin/diphtheria toxin conjugate.